Determining the Health Problems Experienced by Young Adults in Turkey, Who Received the COVID-19 Vaccine
Abstract
:1. Introduction
2. Material and Methods
2.1. Research Design
2.2. Sample of the Research
2.3. Data Collection Tools
2.4. Statistical Analysis
2.5. Ethical Aspect
3. Results
4. Discussion
5. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Cascella, M.; Rajnik, M.; Aleem, A.; Dulebohn, S.C.; Di Napoli, R. Features, Evaluation, and Treatment of Coronavirus (COVID-19); StatPearls: Treasure Island, FL, USA, 2022. [Google Scholar]
- Yuan, K.; Gong, Y.M.; Liu, L.; Sun, Y.K.; Tian, S.S.; Wang, Y.J.; Zhong, Y.; Zhang, A.-Y.; Su, S.-Z.; Liu, X.X.; et al. Prevalence of post traumatic stres disorder after infectious disease pandemics in the twenty-first century, including COVID-19: A meta-analysis and systematic review. MolPsychiatry 2021, 26, 4982–4998. [Google Scholar]
- Guan, W.-J.; Ni, Z.-Y.; Hu, Y.U.; Liang, W.-H.; Ou, C.-Q.; He, J.-X.; Liu, L.; Shan, H.; Lei, C.-L.; Hui, D.S.C.; et al. Clinical characteristics of corona virus disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef] [PubMed]
- Wu, Z.; McGoogan, J.M. Characteristics of and important lessons from the corona virus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the chinese center for disease control and prevention. JAMA 2020, 323, 1239–1242. [Google Scholar] [CrossRef]
- Zhang, Q.; Wang, Z.; Lv, Y.; Zhao, J.; Dang, Q.; Xu, D.; Zhao, D.; Liu, H.; Wang, Z.; Zhao, X.; et al. Clinical features and prognostic factors of patients with COVID-19 in Henan Province, China. Hum. Cell. 2021, 34, 419–435. [Google Scholar] [CrossRef] [PubMed]
- Ismail, A.A. SARS-CoV-2 (COVID-19): A short update on molecular biochemistry, pathology, diagnosis and therapeutic strategies. Ann. Clin. Biochem. 2022, 59, 59–64. [Google Scholar] [CrossRef] [PubMed]
- Zemlin, A.E.; Wiese, O.J. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). Ann. Clin. Biochem. 2020, 57, 339–350. [Google Scholar] [CrossRef]
- Masters, P.S.; Perlman, S. Coronaviridae. Fields Virol. 2013, 1, 825–858. [Google Scholar]
- Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science 2020, 367, 1444–1448. [Google Scholar] [CrossRef]
- Tang, T.; Bidon, M.; Jaimes, J.A.; Whittaker, G.R.; Daniel, S. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antivir. Res. 2020, 178, 104792. [Google Scholar] [CrossRef]
- Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Wang, F.S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020, 8, 420–422. [Google Scholar] [CrossRef]
- Ryan, D.J.; Toomey, S.; Madden, S.F.; Casey, M.; Breathnach, O.S.; Morris, P.G.; Hennessy, B.T. Use of exhaled breath condensate (EBC) in the diagnosis of SARS-CoV-2 (COVID-19). Thorax 2021, 76, 86–88. [Google Scholar] [CrossRef] [PubMed]
- Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Process. Available online: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_02April2022.pdf (accessed on 15 July 2022).
- David, S.S.B.; Gez, S.B.; Rahamim-Cohen, D.; Shamir-Stein, N.A.; Lerner, U.; Zohar, A.E. Immediate side effects of Comirnaty COVID-19 vaccine: A nationwide survey of vaccinated people in Israel, December 2020 to March 2021. Eurosurveillance 2022, 27, 2100540. [Google Scholar]
- Dighriri, I.M.; Alhusayni, K.M.; Mobarki, A.Y.; Aljerary, I.S.; Alqurashi, K.A.; Aljuaid, F.A.; Almutairi, A.N. Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review. Cureus 2022, 14, e23526. [Google Scholar] [CrossRef] [PubMed]
- Picone, V.; Martora, F.; Fabbrocini, G.; Marano, L. “Covid arm”: Abnormal side effect after Moderna COVID-19 vaccine. Dermatol. Ther. 2022, 35, e15197. [Google Scholar] [CrossRef]
- Consoli, S.; Dono, F.; Evangelista, G.; D’Apolito, M.; Travaglini, D.; Onofrj, M.; Bonanni, L. Status migrainosus: A potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—A case report. Neurol. Sci. 2022, 43, 767–770. [Google Scholar] [CrossRef] [PubMed]
- Lippi, G.; Mattiuzzi, C.; Henry, B.M. Mild adverse reactions after COVID-19 vaccination: Updated analysis of Italian Medicines Agency data. Mol. Biol. 2021. [Google Scholar] [CrossRef]
- World Health Organization. Global Vaccine Action Plan; World Health Organization: Geneva, Switzerland, 2013.
- Doherty, T.M.; Di Pasquale, A.; Michel, J.P.; Del Giudice, G. Precision medicine and vaccination of older adults: From reactive to proactive (a mini-review). Gerontology 2020, 66, 238–248. [Google Scholar] [CrossRef]
- Rogers, M.A.; Basu, T.; Kim, C. Lower incidence rate of type 1 diabetes after receipt of the rotavirus vaccine in the United States, 2001–2017. Sci. Rep. 2019, 9, 7727. [Google Scholar] [CrossRef] [PubMed]
- Perrett, K.P.; Jachno, K.; Nolan, T.M.; Harrison, L.C. Association of rotavirus vaccination with the incidence of type 1 diabetes in children. JAMA Pediatrics 2019, 173, 280–282. [Google Scholar] [CrossRef]
- Fountoulaki, K.; Tsiodras, S.; Polyzogopoulou, E.; Olympios, C.; Parissis, J. Beneficial effects of vaccination on cardiovascular events: Myocardial infarction, stroke, heart failure. Cardiology 2018, 141, 98–106. [Google Scholar] [CrossRef]
- Davis, M.M.; Taubert, K.; Benin, A.L.; Brown, D.W.; Mensah, G.A.; Baddour, L.M.; Krumholz, H.M. Influenza vaccination as secondary prevention for cardiovascular disease: A science advisory from the American Heart Association/American College of Cardiology. J. Am. Coll. Cardiol. 2006, 48, 1498–1502. [Google Scholar] [CrossRef] [PubMed]
- Philip, R.K.; Attwell, K.; Breuer, T.; Di Pasquale, A.; Lopalco, P.L. Life-course immunization as a gateway to health. Expert Rev. Vaccines 2018, 17, 851–864. [Google Scholar] [CrossRef] [PubMed]
- Michel, J.P. The well-known and less well-known benefits of vaccines. Aging Clin. Exp. Res. 2020, 32, 1401–1404. [Google Scholar] [CrossRef] [PubMed]
- Zhang, F.; Or, P.P.L.; Chung, J.W.Y. The effects of health literacy in influenza vaccination competencies among community-dwelling older adults in Hong Kong. BMC Geriatr. 2020, 20, 103. [Google Scholar] [CrossRef] [PubMed]
- Michel, J.P.; Ecarnot, F. Healthy Ageing and Vaccines: Application of the P4 Medicine Concept to Immunizations. Gerontology 2022, 68, 481–487. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://saglik.gov.tr/ (accessed on 15 July 2022).
- Walsh, E.E.; Frenck, R.W., Jr.; Falsey, A.R.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Mulligan, M.J.; Bailey, R.; et al. Safetyandimmunogenicity of two RNA-based COVID-19 vaccinecandidates. N. Engl. J. Med. 2020, 383, 2439–2450. [Google Scholar] [CrossRef] [PubMed]
- Mallapaty, S. China COVID vaccine reports mixed results—What does that mean for the pandemic? Nature 2021, 15, 4–6. [Google Scholar] [CrossRef]
- Available online: https://www.tuseb.gov.tr/ (accessed on 15 July 2022).
- Truong, D.T.; Dionne, A.; Muniz, J.C.; McHugh, K.E.; Portman, M.A.; Lambert, L.M.; Newburger, J.W. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: Suspected myocarditis after COVID-19 vaccination. Circulation 2022, 145, 345–356. [Google Scholar] [CrossRef]
- Okamoto, Y.; Hiyama, T.; Miyake, Y.; Yoshino, A.; Miyauchi, S.; Tanaka, J. Attitudes and Behavior toward COVID-19 Vaccination in Japanese University Students: A Cross-Sectional Study. Vaccines 2022, 10, 863. [Google Scholar] [CrossRef]
- Mannan, D.K.A.; Farhana, K.M. Knowledge, attitude and acceptance of a COVID-19 vaccine: A global cross-sectional study. Int. Res. J. Bus. Soc. Sci. 2020, 6, 8–11. [Google Scholar] [CrossRef]
- Marshall, M.; Ferguson, I.D.; Lewis, P.; Jaggi, P.; Gagliardo, C.; Collins, J.S.; Guzman-Cottrill, J.A. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics 2021, 148, e2021052478. [Google Scholar] [CrossRef] [PubMed]
- Moeller, K.E.; Meeks, M.; Reynoldson, J.; Douglass, M. Implementation and Outcomes of COVID-19 Vaccinations at a Child and Adolescent Psychiatric Hospital. J. Am. Acad. Child Adolesc. Psychiatry 2021, 60, 1332. [Google Scholar] [CrossRef] [PubMed]
- Riad, A.; Pokorná, A.; Klugarová, J.; Antalová, N.; Kantorová, L.; Koščík, M.; Klugar, M. Side effects of mRNA-based COVID-19 vaccines among young adults (18–30 years old): An independent post-marketing study. Pharmaceuticals 2021, 14, 1049. [Google Scholar] [CrossRef] [PubMed]
- Meylan, S.; Livio, F.; Foerster, M.; Genoud, P.J.; Marguet, F.; Wuerzner, G.; CHUV COVID Vaccination Center. Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension 2021, 77, e56–e57. [Google Scholar] [CrossRef] [PubMed]
- Samuel, S.M.; Varghese, E.; Triggle, C.R.; Büsselberg, D. COVID-19 Vaccines and Hyperglycemia—Is There a Need for Postvaccination Surveillance? Vaccines 2022, 10, 454. [Google Scholar] [CrossRef] [PubMed]
- Male, V. Menstrual changes after COVID-19 vaccination. BMJ 2021, 374, n2211. [Google Scholar] [CrossRef]
- Saeed, M.A.M.; Mohamed, A.H.; Owaynat, A.H. Cholecalciferol level and its impact on COVID-19 patients. Egypt. J. Intern. Med. 2022, 34, 23. [Google Scholar] [CrossRef]
- Calder, P.C.; Carr, A.C.; Gombart, A.F.; Eggersdorfer, M. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients 2020, 12, 1181. [Google Scholar] [CrossRef] [Green Version]
Features | n | % | |
---|---|---|---|
Gender | Female | 266 | 45.1 |
Male | 324 | 54.90 | |
Average age | 20.74 ± 2.32 | ||
Living place | Village-county | 102 | 17.3 |
City | 284 | 48.1 | |
Big city | 204 | 34.6 | |
Family format | Nuclear family | 454 | 76.9 |
Extended family | 136 | 23.1 | |
Working status | Working | 70 | 11.9 |
Inoperative | 520 | 88.1 | |
Income status | Income less than expenses | 244 | 41.4 |
Income equal to expenses | 308 | 52.2 | |
Income more than expenses | 38 | 6.4 | |
Marital status | Single | 30 | 5.1 |
Married | 560 | 94.9 | |
Class | 1st Class | 370 | 62.7 |
2nd Class | 182 | 30.8 | |
3rd Class | 26 | 4.4 | |
4th Class | 12 | 2.0 | |
Place of residence while studying | Dormitory | 382 | 64.7 |
Student house | 76 | 12.9 | |
Family | 32 | 5.4 | |
Other | 100 | 16.9 |
n | % | ||
---|---|---|---|
Status of getting expert information about COVID-19 | Informed | 252 | 42.7 |
Not informed | 338 | 57.3 | |
Source of information about COVID-19 | Doctor | 184 | 73.01 |
Nurse | 40 | 15.87 | |
Health employee | 28 | 11.11 | |
Chronic disease status | Yes | 40 | 6.8 |
No | 550 | 93.2 | |
COVID-19 vaccination status | Vaccinated | 590 | 100 |
Unvaccinated | 0 | 0 | |
The name of the COVID-19 vaccine | BioNTech | 498 | 84.4 |
Sinovac | 89 | 15.1 | |
Turkovac | 3 | 0.5 | |
The number of COVID-19 doses | One dose | 91 | 15.4 |
Two doses | 397 | 67.3 | |
Three doses | 98 | 16.6 | |
Four doses | 4 | 0.7 | |
COVID-19 health problems after vaccination | Yes | 212 | 35.9 |
No | 344 | 58.3 | |
Health problems after COVID-19 Vaccine | Fatigue | 24 | 4.1 |
Cough | 6 | 1.0 | |
Sleep disorders | 6 | 1.0 | |
Psychological | 4 | 0.7 | |
Heart ache feeling | 6 | 1.0 | |
Headache | 2 | 0.3 | |
Sweating | 2 | 0.3 | |
Arm pain | 2 | 0.3 | |
Fatigue, sleep disturbance | 12 | 2.0 | |
Fatigue, sweating | 4 | 0.7 | |
Sleep disorder, sweating | 2 | 0.3 | |
Weakness, cough, shortness of breath | 2 | 0.3 | |
Fatigue, sleep disturbance, sweating | 2 | 0.3 | |
Sleep disorder, psychological, sweating | 2 | 0.3 | |
Unspecified | 136 | 22.54 | |
Duration of health problems after vaccination (days) | 1 | 40 | 19.05 |
2 | 84 | 40.00 | |
3 | 40 | 19.05 | |
4 | 6 | 2.86 | |
5 | 8 | 3.81 | |
6 | 2 | 0.95 | |
7 | 30 | 14.29 | |
8 and above | 2 | 0.95 | |
The status of having an analysis regarding post-vaccine health problems | Yes | 42 | 7.1 |
No | 548 | 92.9 | |
The state of being different from the results of the test for health problems after vaccination | Yes | 20 | 3.4 |
No | 570 | 96.6 | |
Occurrence of post-vaccine high blood pressure disorder | Yes | 52 | 8.8 |
No | 538 | 91.2 | |
Post-vaccine high blood pressure diagnosis status | Yes | 22 | 3.7 |
No | 568 | 96.3 | |
Presence of high glycemia after vaccination | Yes | 38 | 6.4 |
No | 552 | 93.6 | |
Diagnosis of post-vaccine diabetes mellitus | Yes | 16 | 2.7 |
No | 574 | 97.3 | |
Menstrual cycle irregularity status after vaccination | Yes | 54 | 20.30 |
No | 212 | 79.69 | |
Pre-vaccine menstrual cycle irregularity | Yes | 58 | 21.80 |
No | 208 | 78.19 | |
Status of seeing a doctor due to menstrual cycle irregularity after vaccination | Yes | 28 | 10.52 |
No | 238 | 89.47 | |
Status of receiving treatment for menstrual cycle irregularity after vaccination | Yes | 28 | 10.52 |
No | 238 | 89.47 | |
Case of applying to a doctor due to irregularity in menstrual cycle before vaccination | Yes | 16 | 6.01 |
No | 250 | 93.98 | |
Receiving treatment due to irregularity in menstrual cycle before vaccination | Yes | 16 | 6.01 |
No | 250 | 93.98 | |
Weight gain after vaccination * | Yes | 72 | 12.2 |
No | 518 | 87.8 | |
Reason for weight gain after vaccination | Appetite | 46 | 63.89 |
Not doing sports | 16 | 22.22 | |
Sourced from what they eat | 4 | 5.56 | |
Vaccine | 6 | 8.33 | |
Cough persistence | Yes | 54 | 9.2 |
No | 536 | 90.8 | |
Receiving treatment for cough | Yes | 26 | 4.4 |
No | 564 | 95.6 | |
Usage status of herbal product | Yes | 54 | 9.2 |
No | 536 | 90.8 | |
Product used as herbal product | Vitamin | 38 | 70.37 |
Black seeds | 16 | 29.63 | |
Herbal product status before vaccination | Yes | 22 | 3.7 |
No | 568 | 96.3 | |
Status of herbal product used after vaccination | Yes | 32 | 5.42 |
No | 556 | 94.57 |
Features | Yes | No | ||
---|---|---|---|---|
n | % | n | % | |
Working Status ** | ||||
Yes | 14 | 6.6 | 56 | 14.8 |
No | 198 | 93.4 | 322 | 85.2 |
Test/p | χ2 = 7.990 p = 0.005 | |||
Income status | ||||
Income less than expenses | 90 | 42.5 | 154 | 40.7 |
Income equal to expenses | 108 | 50.9 | 200 | 52.9 |
Income higher than expenses | 14 | 6.6 | 24 | 6.3 |
Test/p | χ2 = 0.211 p = 0.9 | |||
Chronic Disease Status ** | ||||
Yes | 14 | 6.6 | 26 | 6.9 |
No | 198 | 93.4 | 352 | 93.1 |
Test/p | χ2 = 0.000 p = 0.899 | |||
Vaccine Name | ||||
BioNTech | 188 | 88.7 | 310 | 82.0 |
Sinovac | 23 | 10.8 | 66 | 17.5 |
Turkovac | 1 | 0.5 | 2 | 0.5 |
Test/p | χ2 = 4.660 p = 0.097 | |||
Number of Vaccinations * | ||||
One dose | 22 | 10.4 | 69 | 18.3 |
Two doses | 142 | 67.0 | 255 | 67.5 |
Three doses | 48 | 22.6 | 54 | 14.3 |
Test/p | χ2 = 10.953 p = 0.004 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Akarsu, G.D. Determining the Health Problems Experienced by Young Adults in Turkey, Who Received the COVID-19 Vaccine. Vaccines 2022, 10, 1526. https://doi.org/10.3390/vaccines10091526
Akarsu GD. Determining the Health Problems Experienced by Young Adults in Turkey, Who Received the COVID-19 Vaccine. Vaccines. 2022; 10(9):1526. https://doi.org/10.3390/vaccines10091526
Chicago/Turabian StyleAkarsu, Gökhan Doğukan. 2022. "Determining the Health Problems Experienced by Young Adults in Turkey, Who Received the COVID-19 Vaccine" Vaccines 10, no. 9: 1526. https://doi.org/10.3390/vaccines10091526
APA StyleAkarsu, G. D. (2022). Determining the Health Problems Experienced by Young Adults in Turkey, Who Received the COVID-19 Vaccine. Vaccines, 10(9), 1526. https://doi.org/10.3390/vaccines10091526